{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:07:35Z","timestamp":1792102055287,"version":"4.4.0"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec013\">\n<jats:title>Background<\/jats:title>\n<jats:p>Type 1 diabetes (T1D) is an autoimmune condition characterized by the destruction of insulin-producing beta cells in the pancreas. Anti-Thymocyte Globulin (ATG) has emerged as a promising immunomodulatory therapy aimed at preserving beta-cell function and altering the disease course. This systematic review synthesizes current evidence from the clinical trials evaluating the efficacy and safety of low-dose ATG in individuals with T1D.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec014\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a comprehensive literature search of electronic databases, including PubMed (MEDLINE), Science Direct, Scopus, EMBASE, and ClinicalTrials.gov, to identify studies investigating ATG in T1D in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. The Joanna Briggs Institute (JBI) Critical Appraisal Tools for randomized clinical trials and case-control studies were used to assess the quality and evaluate the risk of bias in the eligible studies.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec015\">\n<jats:title>Results<\/jats:title>\n<jats:p>The primary outcomes assessed were preservation of C-peptide levels, glycemic control, and adverse events. Results indicated that ATG showed potential in preserving beta-cell function and improving clinical outcomes in recent-onset T1D. However, the incidence of adverse events, such as cytokine release syndrome and lymphopenia, necessitated careful monitoring and management.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec016\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Low-dose ATG presents a promising therapeutic approach for modifying the progression of T1D. While early-phase trials demonstrate potential benefits in preserving beta-cell function, further large-scale, long-term studies are essential to establish optimal dosing regimens, long-term efficacy, and safety profiles. This review highlights the importance of continued research to fully elucidate the role of ATG in T1D management.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0323642","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:53:24Z","timestamp":1747166004000},"page":"e0323642","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic potential of anti-thymocyte globulin in type 1 diabetes: A systematic review"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0894-237X","authenticated-orcid":true,"given":"Rahul","family":"Mittal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0302-7036","authenticated-orcid":true,"given":"Keelin","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8211-1617","authenticated-orcid":true,"given":"Joana R. N.","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Juneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mannat","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khemraj","family":"Hirani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"9911","key":"pone.0323642.ref001","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","article-title":"Type 1 diabetes","volume":"383","author":"MA Atkinson","year":"2014","journal-title":"Lancet"},{"issue":"10138","key":"pone.0323642.ref002","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"LA DiMeglio","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"pone.0323642.ref003","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41577-023-00985-4","article-title":"The immunology of type 1 diabetes","volume":"24","author":"KC Herold","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"pone.0323642.ref004","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41574-019-0254-y","article-title":"The heterogeneous pathogenesis of type 1 diabetes mellitus","volume":"15","author":"J Ilonen","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"pone.0323642.ref005","doi-asserted-by":"crossref","first-page":"1335435","DOI":"10.3389\/fendo.2024.1335435","article-title":"Gene-environment interaction in the pathophysiology of type 1 diabetes","volume":"15","author":"R Mittal","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"pone.0323642.ref006","article-title":"New advances in type 1 diabetes","volume":"384","author":"S Subramanian","year":"2024","journal-title":"BMJ"},{"issue":"1","key":"pone.0323642.ref007","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.117.310221","article-title":"Highlighting diabetes mellitus: the epidemic continues","volume":"38","author":"AM Schmidt","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"pone.0323642.ref008","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"GA Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"pone.0323642.ref009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12933-024-02136-y","article-title":"The double burden: type 1 diabetes and heart failure-a comprehensive review","volume":"23","author":"MT Juli\u00e1n","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"pone.0323642.ref010","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ecl.2010.05.011","article-title":"Epidemiology of type 1 diabetes","volume":"39","author":"DM Maahs","year":"2010","journal-title":"Endocrinol Metab Clin North Am"},{"key":"pone.0323642.ref011","doi-asserted-by":"crossref","first-page":"117158","DOI":"10.1016\/j.atherosclerosis.2023.06.005","article-title":"Cardiovascular disease in type 1 diabetes, an underestimated danger: Epidemiological and pathophysiological data","volume":"394","author":"B Verg\u00e8s","year":"2024","journal-title":"Atherosclerosis"},{"issue":"1","key":"pone.0323642.ref012","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40842-024-00174-9","article-title":"Diabetic ketoacidosis in an adult with beta-ketothiolase deficiency (BKD) involving a novel ACAT1 variant\u00a0: first report of established diabetes in BKD and a review of the literature","volume":"10","author":"XM Zhen","year":"2024","journal-title":"Clin Diabetes Endocrinol"},{"issue":"3","key":"pone.0323642.ref013","doi-asserted-by":"crossref","first-page":"101418","DOI":"10.1016\/j.disamonth.2022.101418","article-title":"Diabetic ketoacidosis","volume":"69","author":"APP Calimag","year":"2023","journal-title":"Dis Mon"},{"issue":"1","key":"pone.0323642.ref014","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41572-020-0165-1","article-title":"Diabetic ketoacidosis","volume":"6","author":"KK Dhatariya","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"pone.0323642.ref015","doi-asserted-by":"crossref","first-page":"17016","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 diabetes mellitus","volume":"3","author":"A Katsarou","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"pone.0323642.ref016","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ecl.2010.05.009","article-title":"Complications of type 1 diabetes","volume":"39","author":"LY Melendez-Ramirez","year":"2010","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"pone.0323642.ref017","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2841","article-title":"Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis, and diagnosis","volume":"33","author":"N Papadopoulou-Marketou","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"pone.0323642.ref018","article-title":"Type 1 Diabetes Mellitus","volume":"175","author":"FZ Syed","year":"2022","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0323642.ref019","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40618-024-02406-2","article-title":"Diabetes and long duration leading to speech-, low\/mid-, and high- frequency hearing loss: current evidence from the China National Health Survey 2023","volume":"48","author":"H Huang","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"pone.0323642.ref020","article-title":"The impact of diabetes mellitus on sensorineural hearing loss: a cross-sectional study in Eastern India","volume":"16","author":"UP Mishra","year":"2024","journal-title":"Cureus"},{"issue":"7","key":"pone.0323642.ref021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0305617","article-title":"Diabetes mellitus, hearing loss, and therapeutic interventions: a systematic review of insights from preclinical animal models","volume":"19","author":"R Mittal","year":"2024","journal-title":"PLoS One"},{"issue":"2","key":"pone.0323642.ref022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0298457","article-title":"A systematic review of the association of Type I diabetes with sensorineural hearing loss","volume":"19","author":"R Mittal","year":"2024","journal-title":"PLoS One"},{"key":"pone.0323642.ref023","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2147\/JMDH.S454678","article-title":"Association between triglyceride-glucose index and hearing threshold shifts of adults in the united states: National health and nutrition examination survey, 2015-2016","volume":"17","author":"J-Y Pan","year":"2024","journal-title":"J Multidiscip Healthc"},{"key":"pone.0323642.ref024","doi-asserted-by":"crossref","first-page":"109072","DOI":"10.1016\/j.heares.2024.109072","article-title":"Associations between diabetes mellitus and sensorineural hearing loss from humans and animal studies","volume":"450","author":"ED Williams","year":"2024","journal-title":"Hear Res"},{"issue":"8","key":"pone.0323642.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0308556","article-title":"Systematic review of translational insights: neuromodulation in animal models for diabetic peripheral neuropathy","volume":"19","author":"R Mittal","year":"2024","journal-title":"PLoS One"},{"issue":"6","key":"pone.0323642.ref026","article-title":"Prevalence and severity of sensorineural hearing loss in diabetic and hypertensive patients: a comparative cross-sectional study","volume":"16","author":"MM Mohammed","year":"2024","journal-title":"Cureus"},{"key":"pone.0323642.ref027","volume-title":"Diabetic foot ulcer","author":"C Packer","year":"2025"},{"issue":"4","key":"pone.0323642.ref028","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2337\/dc19-2292","article-title":"Risk factors for first and subsequent CVD events in Type 1 diabetes: The DCCT\/EDIC study","volume":"43","author":"I Bebu","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"pone.0323642.ref029","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"JM Forbes","year":"2013","journal-title":"Physiol Rev"},{"issue":"7","key":"pone.0323642.ref030","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.2337\/dc22-0042","article-title":"Case fatality of patients with type 1 diabetes after myocardial infarction","volume":"45","author":"AM Kerola","year":"2022","journal-title":"Diabetes Care"},{"issue":"15","key":"pone.0323642.ref031","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in Type 1 and Type 2 diabetes","volume":"376","author":"A Rawshani","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0323642.ref032","article-title":"2. Classification and diagnosis of diabetes: standards of care in diabetes-2023","volume":"46","author":"NA ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"12","key":"pone.0323642.ref033","doi-asserted-by":"crossref","first-page":"10012","DOI":"10.3390\/ijms241210012","article-title":"Anti-Islet autoantibodies in Type 1 diabetes","volume":"24","author":"E Kawasaki","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"pone.0323642.ref034","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4239\/wjd.v4.i5.227","article-title":"Sequential elevation of autoantibodies to thyroglobulin and glutamic acid decarboxylase in type 1 diabetes","volume":"4","author":"E Kawasaki","year":"2013","journal-title":"World J Diabetes"},{"issue":"10","key":"pone.0323642.ref035","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"RA Insel","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"pone.0323642.ref036","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/jcm14020383","article-title":"Pre-type 1 diabetes in adolescents and teens: screening, nutritional interventions, beta-cell preservation, and psychosocial impacts","volume":"14","author":"B Sundheim","year":"2025","journal-title":"J Clin Med"},{"issue":"1","key":"pone.0323642.ref037","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s43856-024-00478-y","article-title":"Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review","volume":"4","author":"JL Felton","year":"2024","journal-title":"Commun Med (Lond)"},{"issue":"2","key":"pone.0323642.ref038","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2337\/dc23-1750","article-title":"Low-dose antithymocyte globulin: a pragmatic approach to treating stage 2 type 1 diabetes","volume":"47","author":"TP Foster","year":"2024","journal-title":"Diabetes Care"},{"issue":"3","key":"pone.0323642.ref039","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/pedi.12812","article-title":"Predicting progression to type 1 diabetes from ages 3 to 6 in islet autoantibody positive TEDDY children","volume":"20","author":"LM Jacobsen","year":"2019","journal-title":"Pediatr Diabetes"},{"issue":"23","key":"pone.0323642.ref040","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2013.6285","article-title":"Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children","volume":"309","author":"AG Ziegler","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"pone.0323642.ref041","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1600-6143.2011.03978.x","article-title":"Ex vivo expansion of human Tregs by rabbit ATG is dependent on intact STAT3-signaling in CD4\u207a T cells and requires the presence of monocytes","volume":"12","author":"O Boenisch","year":"2012","journal-title":"Am J Transplant"},{"issue":"3","key":"pone.0323642.ref042","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/cells12030382","article-title":"Antithymocyte Globulin Inhibits CD8+ T Cell Effector Functions via the Paracrine Induction of PDL-1 on Monocytes","volume":"12","author":"D Copic","year":"2023","journal-title":"Cells"},{"issue":"8","key":"pone.0323642.ref043","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/intimm\/dxm078","article-title":"Anti-thymocyte globulin (ATG) prevents autoimmune encephalomyelitis by expanding myelin antigen-specific Foxp3+ regulatory T cells","volume":"19","author":"DT Chung","year":"2007","journal-title":"Int Immunol"},{"issue":"4","key":"pone.0323642.ref044","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.immuni.2010.04.002","article-title":"Immunotherapy of type 1 diabetes: where are we and where should we be going?","volume":"32","author":"X Luo","year":"2010","journal-title":"Immunity"},{"issue":"7","key":"pone.0323642.ref045","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond","volume":"21","author":"M Mohty","year":"2007","journal-title":"Leukemia"},{"issue":"5","key":"pone.0323642.ref046","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11892-019-1144-3","article-title":"Current status on immunological therapies for type 1 diabetes mellitus","volume":"19","author":"GLL Xin","year":"2019","journal-title":"Curr Diab Rep"},{"issue":"6","key":"pone.0323642.ref047","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00125-016-3917-4","article-title":"Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial","volume":"59","author":"SE Gitelman","year":"2016","journal-title":"Diabetologia"},{"issue":"9","key":"pone.0323642.ref048","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.2337\/db09-1264","article-title":"A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice","volume":"59","author":"A Vergani","year":"2010","journal-title":"Diabetes"},{"issue":"1","key":"pone.0323642.ref049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053797","article-title":"Prolonged, low-dose anti-thymocyte globulin, combined with CTLA4-Ig, promotes engraftment in a stringent transplant model","volume":"8","author":"F D\u2019Addio","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"pone.0323642.ref050","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2337\/dc18-0494","article-title":"Low-Dose Anti-Thymocyte Globulin (ATG) preserves \u03b2-cell function and improves HbA1c in new-onset type 1 diabetes","volume":"41","author":"MJ Haller","year":"2018","journal-title":"Diabetes Care"},{"issue":"11","key":"pone.0323642.ref051","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders","volume":"62","author":"KC Herold","year":"2013","journal-title":"Diabetes"},{"issue":"11","key":"pone.0323642.ref052","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.2337\/db13-0236","article-title":"Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Prot\u00e9g\u00e9 trial","volume":"62","author":"W Hagopian","year":"2013","journal-title":"Diabetes"},{"issue":"7","key":"pone.0323642.ref053","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for Type 1 diabetes","volume":"381","author":"KC Herold","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"pone.0323642.ref054","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","article-title":"Teplizumab and \u03b2-cell function in newly diagnosed type 1 diabetes","volume":"389","author":"EL Ramos","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0323642.ref055","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2337\/db19-0057","article-title":"Low-dose anti-thymocyte globulin preserves C-peptide, reduces HbA1c, and increases regulatory to conventional T-cell ratios in new-onset Type 1 diabetes: two-year clinical trial data","volume":"68","author":"MJ Haller","year":"2019","journal-title":"Diabetes"},{"issue":"16","key":"pone.0323642.ref056","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.161812","article-title":"Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes","volume":"8","author":"LM Jacobsen","year":"2023","journal-title":"JCI Insight"},{"issue":"2","key":"pone.0323642.ref057","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2337\/db13-0881","article-title":"Impact of C-peptide preservation on metabolic and clinical outcomes in the diabetes control and complications trial","volume":"63","author":"DCCT\/EDIC Research Group","year":"2014","journal-title":"Diabetes"},{"issue":"4","key":"pone.0323642.ref058","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1172\/JCI134057","article-title":"High residual C-peptide likely contributes to glycemic control in type 1 diabetes","volume":"130","author":"MR Rickels","year":"2020","journal-title":"J Clin Invest"},{"issue":"1","key":"pone.0323642.ref059","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1172\/JCI78492","article-title":"Anti-thymocyte globulin\/G-CSF treatment preserves \u03b2 cell function in patients with established type 1 diabetes","volume":"125","author":"MJ Haller","year":"2015","journal-title":"J Clin Invest"},{"issue":"12","key":"pone.0323642.ref060","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.2337\/db16-0823","article-title":"Antithymocyte globulin plus G-CSF combination therapy leads to sustained immunomodulatory and metabolic effects in a subset of responders with established Type 1 diabetes","volume":"65","author":"MJ Haller","year":"2016","journal-title":"Diabetes"},{"issue":"12","key":"pone.0323642.ref061","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053669","article-title":"Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes","volume":"11","author":"CS Wilhelm-Benartzi","year":"2021","journal-title":"BMJ Open"},{"issue":"6","key":"pone.0323642.ref062","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5500\/wjt.v13.i6.299","article-title":"Anti-thymocyte globulin for treatment of T-cell-mediated allograft rejection","volume":"13","author":"S Acharya","year":"2023","journal-title":"World J Transplant"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:53:37Z","timestamp":1747166017000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323642"}},"subtitle":[],"editor":[{"given":"Shafiya Imtiaz","family":"Rafiqi,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":62,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0323642","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]}}}